Association of a Schizophrenia Risk Variant at the DRD2 Locus with Antipsychotic Treatment Response in First-Episode Psychosis

Schizophrenia Bulletin

Volumn 41, Issue 6, 2015, Pages 1248-1255

  Zhang, Jian Ping ^a,b,c   Robinson, Delbert G ^a,b,c   Gallego, Juan A ^a,b,c   John, Majnu ^a,b,c,d   Yu, Jin ^a   Addington, Jean ^e   Tohen, Mauricio ^f   Kane, John M ^a,b,c   Malhotra, Anil K ^a,b,c   Lencz, Todd ^a,b,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d HOFSTRA UNIVERSITY   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Antipsychotic; DRD2; Pharmacogenetics

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; PROLACTIN; RISPERIDONE; DRD2 PROTEIN, HUMAN; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; ASSESSMENT OF HUMANS; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DSM-IV; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; POSITIVE SYNDROME; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; SCHEDULE FOR ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT; GENE LOCUS; GENETICS; OUTCOME ASSESSMENT; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; FEMALE; GENETIC LOCI; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, DOPAMINE D2; RISK; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84946109029     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv116     Document Type: Article

References (32)

1. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophreniaassociated genetic loci. Nature. 2014;511:421-427.
2. Lencz T, Malhotra AK. Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. Mol Psychiatry. 2015;20:820-826.
3. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1081-1090.
4. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71:1115-1124.
5. Lieberman JA, Stroup TS, McEvoy JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
6. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol. 2011;7:9-37.
7. Lencz T, Robinson DG, Xu K, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry. 2006;163:529-531.
8. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010;167:763-772.
9. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79-104.
10. Trampush JW, Lencz T, DeRosse P, et al. Relationship of cognition to clinical response in first-episode schizophrenia spectrum disorders. Schizo Bull, Nov 2015, Doi: 10.1093/schbul/sbv120
11. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 1995;57:PL103-PL107.
12. Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull. 2002;36:143-164.
13. Robinson DG, Gallego JA, John M, et al. A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3 month outcomes. Schizo Bull, Nov 2015.
14. Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull. 1988;24:112-117.
15. Andreason NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983.
16. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication ADM 76-338. Washington, DC: National Institute of Mental Health; 1976.
17. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
18. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
19. Selya AS, Rose JS, Dierker LC, Hedeker D, Mermelstein RJ. A Practical Guide to Calculating Cohen's f(2), a Measure of Local Effect Size, from PROC MIXED. Front Psychol. 2012;3:111.
20. Howes OD, Kapur S. A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry. 2014;205:1-3.
21. Sarpal DK, Argyelan M, Robinson DG, et al. Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. Am J Psychiatry. In press.
22. Lencz T, Malhotra AK. Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci. 2009;11:405-415.
23. Rummel-Kluge C, Komossa K, Schwarz S, et al. Secondgeneration antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-tohead comparisons. Schizophr Bull. 2012;38:167-177.
24. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148:1474-1486.
25. Muller DJ, Zai CC, Sicard M, et al. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J. 2012;12:156-164.
26. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17:1206-1227.
27. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001;158:360-369.
28. Remington G, Kapur S. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry. 1999;60(suppl 10):15-19.
29. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl). 2000;148:3-15.
30. Lencz T, Robinson DG, Napolitano B, et al. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics. 2010;20:569-572.
31. Malhotra AK, Zhang JP, Lencz T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry. 2012;17:760-769.
32. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400-1411.